Kintor Pharmaceutical Reports 6.0 Million RMB Revenue in H1 2025, Net Loss Widens to 83.3 Million RMB
Reuters
Aug 28
<a href="https://laohu8.com/S/KNTPF">Kintor Pharmaceutical</a> Reports 6.0 Million RMB Revenue in H1 2025, Net Loss Widens to 83.3 Million RMB
Kintor Pharmaceutical Ltd. announced its unaudited interim results for the six months ended 30 June 2025. The company reported a significant increase in revenue, climbing from RMB0 million in the first half of 2024 to RMB6.0 million in the same period of 2025. This rise was primarily driven by the global sales of the new high-end cosmetics brand KOSHINÉ's products. However, the company's net loss also increased by RMB11.8 million, or 16.5%, from RMB71.5 million for the six months ended 30 June 2024 to RMB83.3 million for the same period in 2025, mainly due to higher research and development and marketing costs. Marketing expenses surged by RMB6.5 million, or 369.0%, reflecting increased promotional efforts for KOSHINÉ's cosmetics and raw materials business. As of 30 June 2025, Kintor Pharmaceutical Ltd. maintained cash and cash equivalents of RMB52.9 million, along with unutilised bank facilities of RMB30.0 million. The company is executing plans to support the advancement of its clinical trials and R&D, including the Top-up Placing 2025. The Board has decided not to pay any interim dividend for the six months ended 30 June 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.